Systemic and targeted therapies for early-stage lung cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Control: Journal of the Moffitt Cancer Cente

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107327481402100104PMID 24357738
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC).

  2016cited by this paper
• Non-small Cell Lung Cancer

  2016cited by this paper
• Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer

  2015cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

  2013cited by this paper
• Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Non-small cell lung cancer.

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Molecular testing of non-small cell lung carcinoma biopsy and cytology specimens.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

  2011cited by this paper
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

  2011cited by this paper
• INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

  2011cited by this paper
• Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

  2011cited by this paper
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

  2011cited by this paper
• Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

  2010cited by this paper
• RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  2010cited by this paper
• RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

  2010cited by this paper
• DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

  2010cited by this paper
• 国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• 9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

  2009cited by this paper
• MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

  2009cited by this paper
• Genetic predictors of MEK dependence in non-small cell lung cancer.

  2008cited by this paper
• Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC)

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

  2008cited by this paper
• Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

  2007cited by this paper
• Chemotherapy and surgery versus surgery alone in non-small cell lung cancer.

  2007cited by this paper
• STEREOTACTIC RADIATION THERAPY WORKSHOP Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers

  2007cited by this paper
• In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression

  2007cited by this paper
• Adjuvant Chemotherapy for Non-small Cell Lung Cancer

  2007cited by this paper
• Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.

  2007cited by this paper
• DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

  2007cited by this paper
• Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

  2007cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

  2006cited by this paper
• A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer

  2006cited by this paper
• Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features

  2006cited by this paper
• A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2006cited by this paper
• Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out?

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Angiogenesis in life, disease and medicine

  2005cited by this paper
• S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results

  2005cited by this paper
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

  2005cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

  2004cited by this paper
• BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

  2004cited by this paper
• Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

  2003cited by this paper
• Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.

  2001cited by this paper
• [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer].

  2001cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

  2000cited by this paper
• Chemotherapy in Non-Small Cell Lung Cancer

  2000cited by this paper
• A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

  2000cited by this paper
• Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine

  1998cited by this paper
• Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

  1998cited by this paper
• Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

  1997cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Tumoral vascularity as a prognostic factor in cancer.

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• The implications of angiogenesis for the biology and therapy of cancer metastasis.

  1994cited by this paper

• A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes.

  2025cites this paper
• Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival

  2022cites this paper
• miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway

  2022cites this paper
• A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer

  2021cites this paper
• Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer

  2021cites this paper
• Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data

  2021cites this paper
• Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer

  2021cites this paper
• Nelfinavir restricts A549 cell growth by inhibiting STAT3 signaling

  2021cites this paper
• miR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer

  2020cites this paper
• microRNA-21 upregulates YAP by inhibiting transcription factor RUNX1 to regulate immunosuppressive ability of myeloid-derived suppressor cells in lung cancer

  2020cites this paper
• Prognostic Values of Platelet-Associated Indicators in Resectable Lung Cancers

  2019cites this paper
• Recurrence in patients that underwent surgery for lung cancer

  2018cites this paper
• Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer

  2018cites this paper
• A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer

  2018cites this paper
• Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer

  2018cites this paper
• SPARC acts as a mediator of TGF‐&bgr;1 in promoting epithelial‐to‐mesenchymal transition in A549 and H1299 lung cancer cells

  2018cites this paper
• Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.

  2018cites this paper
• Gene expression of MAGE‐A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non–small cell lung cancer patients

  2017cites this paper
• Phosphodiesterase type 5 and cancers: progress and challenges

  2017cites this paper
• Current status of research and treatment for non-small cell lung cancer in never-smoking females

  2017cites this paper
• Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

  2016cites this paper
• A 10‐Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non–Small Cell Lung Cancer

  2016cites this paper
• Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

  2016cites this paper
• Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway

  2016cites this paper
• Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.

  2016cites this paper
• CHRONIC MYELOID LEUKEMIA TREATED WITH A TYROSINE INHIBITOR KINASE - PUBLIC HEALTH ASPECTS

  year unknowncites this paper